三质×四通路交互项的功效边界:12 格交叉设计到底要多少人?

Written by

in

Language

Evidence level: B

辨证声疗的整个体系押注在”体质×通路”交互项上,而交互项恰恰是所有统计检验里最费样本的那一个——三质×四通路看着只有 12 格,但要检出它所需的样本量,可能比检出主效应多出一个数量级。

正文

上一篇把”三质×四通路交叉盲法 RCT”的裁决逻辑讲清楚了:这场试验的头号终点不是主效应,而是交互项。这一篇要回答一个更冷的问题——这场试验要多少人,才配说”交互不显著”?

先说结论:如果交互效应只有主效应的三分之一到五分之一,那么一场按主效应配功效的试验,大概率什么都测不出来。这不是悲观,是算出来的。

交互项的方差天然是主效应的四倍。 Leon 与 Heo 在混合效应线性回归模型下给出了这个结果的公式与模拟验证:在 2×2 因子设计中,交互项的方差是主效应方差的四倍,因此要检出同等量级的交互,样本量要翻四倍(PMID 20084090)。Brookes 等人用模拟把这件事量化得更狠:一场对总体效应有 80% 功效的试验,对同等量级的交互只有 29% 的功效;要让交互达到同样功效,样本量需膨胀四倍,而当交互小于总体效应的 20% 时,膨胀系数会飙升到 100 倍以上(PMID 15066682、PMID 11701102)。换句话说,主效应四十来人就能测出的东西(对照 PMID 40547334 的四方式对照),交互项可能要四千人。

交叉设计能省样本,但省不到交互项头上。 交叉设计的效率来自”每个受试者当自己的对照”,把受试者间的方差从比较里消掉。当受试者间方差是测量误差方差的两倍时,平行组要六倍的人才能达到交叉组的同等功效(PMID 28810895 对两类方差成分的图解;PMID 9855035 给出两周期重复测量交叉设计的样本量公式)。但这里有个关键错配:三质是受试者间变量,通路是受试者内变量,交互项落在”跨层”位置上。跨层交互不能靠增加受试者内测量次数来救——Arend 与 Schäfer 的两层模型蒙特卡洛教程明确指出:在中等方差成分下,即使上层样本量加到 200 个簇,小的上层直接效应或跨层交互效应依然检不出来(PMID 30265048)。把通路重复测四遍只增加受试者内精度,改变不了”每个体质组只有几十个人”这个硬约束。

功效不足的代价不是”没结论”,是”错误结论”。 一场交互不显著的试验,最容易被读成”通路不分体质、辨证没意义”——但真实结论只是”这次没测出来”。Ferreira 与 Patino 在方法学教程里点破了这个陷阱:样本量不足时,交互项会呈现”某亚组有效、另一亚组无效”的假象,研究者据此下结论,实则只是功效不够(PMID 28746525)。Brookes 的模拟里,仅在一个亚组观察到显著效应的情况在 7%-64% 的模拟中发生(PMID 15066682)。Byth 与 Gebski 的图形化工具则给出另一种可能:交互的存在会反过来削弱主效应的检出(PMID 16279257)——最坏情形是”交互和主效应双双不显著”,一场试验白做。

HRV 自身的测量噪声还要再收一笔税。 交互检验的效应量分母里装着测量误差。短时 HRV 的重测信度并不理想:Pinna 等人在 39 名健康人两日重复测量中发现 ICC 在 0.65-0.88 之间,单个受试者第二次测量可达第一次的 1.9/0.5 倍(SDNN)到 3.5/0.3 倍(LF/HF)的随机波动,估计所需样本量 24-98 人(PMID 17381425);Cipryan 与 Litschmannova 在 99 人里同样发现 HRV 参数存在大的个体内随机变异(PMID 22963409);2025 年一项 49 人的一周重测显示静息 HRV 的 ICC 只有 0.50-0.83、变异系数 5%-41%,频域指标比时域更不稳(PMID 39854840)。这意味着:HRV 终点本身就在吃掉功效,交互项要在噪声之上再被检出,样本量必须再往上加。

结论:功效分析必须用模拟,不能用手算。 三质×四通路是 3(受试者间)×4(受试者内)的混合设计,既有跨层交互、又有交叉设计的方差结构,解析公式算不准。正确做法是蒙特卡洛模拟:设定主效应与交互效应量梯度(如交互 = 主效应的 1/3、1/5)、受试者间与受试者内方差比、以及 12 格每格样本量(30-300/体质组),逐档模拟交互检验的功效,画出”样本量-功效曲面”(方法学参考 PMID 30265048 的 SIMR 教程、PMID 33954914 的混合模型模拟功效、PMID 22350626 的蒙特卡洛映射功效法)。若模拟显示 300 人/体质组仍达不到 80% 功效,那么”以交互为终点”的设计应当放弃,或改为自适应样本量再估计(PMID 30073679 给出交叉试验的盲态与非盲态再估计方法)。

一句话:12 格不等于 12 倍简单。 在谈”通路是否分体质”之前,先算清楚这场试验有没有资格说”不显著”。

证据与局限

已验证: 交互项方差为主效应四倍、需四倍样本(PMID 20084090);80% 功效的总体效应试验对同等交互仅 29% 功效、交互小于 20% 时需膨胀 100 倍以上(PMID 15066682、PMID 11701102);交叉设计对主效应的效率增益与两类方差成分关系(PMID 28810895、PMID 9855035);跨层交互即使 200 簇也难检出小效应(PMID 30265048);交互检验功效不足导致误读(PMID 28746525、PMID 16279257);HRV 重测信度 ICC 0.50-0.88、变异系数最高 41%(PMID 17381425、PMID 22963409、PMID 39854840);蒙特卡洛模拟功效方法(PMID 33954914、PMID 22350626);交叉试验样本量再估计(PMID 30073679)。

部分验证: “交互效应量级为主效应的 1/3-1/5″这一先验来自机制类比——不同体质对不同通路的响应差异应有中等量级,但三质×通路的交互效应量从未被实测,是本文功效曲面设定的关键未知参数。

待验证: 三质×四通路交互项的真实效应量级;12 格交叉设计下达到 80% 功效所需的最小样本量;跨层交互检验相对主效应检验的功效落差具体是多少倍;HRV 测量噪声对交互功效的额外稀释比例;盲态样本量再估计在三质交叉试验中的可行性。

相关阅读

证据等级: B(交互功效四倍规则、跨层交互功效、HRV 信度、模拟功效方法均有 PubMed 直接支撑;”三质×四通路 12 格设计的样本量-功效曲面”无直接研究,属方法学外推加模拟设计推演)
参考文献: PMID 20084090, PMID 15066682, PMID 11701102, PMID 16279257, PMID 28810895, PMID 9855035, PMID 30265048, PMID 28746525, PMID 17381425, PMID 22963409, PMID 39854840, PMID 33954914, PMID 22350626, PMID 30073679, PMID 40547334


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Power Boundaries of the Three-Way by Four-Way Interaction Term: How Many Subjects Are Needed for a 12-Level Crossed Design?

Evidence level: B

The entire system of辨证声疗 (Bian Zheng Sheng Liao) bets on the “Quality × Pathway” interaction term, yet this interaction is precisely the most sample-intensive component in all statistical tests. While the Three-Quality × Four-Pathway design appears to have only 12 cells, the sample size required to detect this interaction may be an order of magnitude larger than that needed for main effects.

Main Text

The previous article clarified the decision logic for a “Three-Quality × Four-Pathway Crossed Blinded RCT”: the primary endpoint of this trial is not the main effect, but the interaction term. This article addresses a colder question: How many subjects are required before one can legitimately claim “no significant interaction”?

Conclusion first: If the interaction effect is only one-third to one-fifth of the main effect, a trial powered for the main effect will likely detect nothing. This is not pessimism; it is calculated.

The variance of the interaction term is naturally four times that of the main effect. Leon and Heo provided the formula and simulation verification under mixed-effects linear regression models: in a 2×2 factorial design, the variance of the interaction term is four times that of the main effect; therefore, detecting an interaction of equivalent magnitude requires quadrupling the sample size (PMID 20084090). Brookes et al. quantified this more severely using simulation: a trial with 80% power for the overall effect has only 29% power for an interaction of the same magnitude; to achieve equivalent power for the interaction, the sample size must expand fourfold, and when the interaction is less than 20% of the overall effect, the inflation factor can soar to over 100 times (PMID 15066682, PMID 11701102). In other words, an effect detectable with forty subjects for the main effect (based on a four-way comparison in PMID 40547334) may require four thousand subjects for the interaction term.

Crossed designs save samples, but not at the cost of the interaction term. The efficiency of crossed designs stems from “each subject serving as their own control,” eliminating between-subject variance from comparisons. When between-subject variance is twice the measurement error variance, parallel groups require six times more subjects to achieve equivalent power compared to crossed groups (PMID 28810895 illustrates the relationship between two variance components; PMID 9855035 provides the sample size formula for two-period repeated-measures crossed designs). However, there is a critical mismatch: Three-Quality is a between-subject variable, while Pathway is an within-subject variable, placing the interaction term in a “cross-layer” position. Cross-layer interactions cannot be rescued by increasing within-subject measurement counts—Arend and Schäfer’s two-level model Monte Carlo tutorial explicitly states that even with the upper-level sample size increased to 200 clusters, small direct effects at the upper level or cross-layer interaction effects remain undetectable under moderate variance components (PMID 30265048). Repeating the Pathway measurement four times only increases within-subject precision; it does not alter the hard constraint that “each Quality group has only dozens of subjects.”

The cost of insufficient power is not “no conclusion,” but “incorrect conclusions.” A trial with a non-significant interaction is most easily misread as “Pathways do not differ by Quality” or “Bian Zheng is meaningless”—but the true conclusion is merely “this time it was not detected.” Ferreira and Patino exposed this trap in their methodological tutorial: when sample size is insufficient, interaction terms can present a false appearance of “effectiveness in one subgroup and ineffectiveness in another,” leading researchers to draw conclusions based on this illusion rather than insufficient power (PMID 28746525). In Brookes’ simulation, scenarios where significance was observed in only one subgroup occurred in 7%-64% of simulations (PMID 15066682). Byth and Gebski’s graphical tool offers another possibility: the existence of an interaction can actually weaken the detection of the main effect (PMID 16279257)—the worst-case scenario is “both interaction and main effect non-significant,” rendering the trial futile.

HRV measurement noise incurs an additional tax. The denominator of the interaction effect size includes measurement error. Short-term HRV retest reliability is not ideal: Pinna et al., in a two-day repeated measurement of 39 healthy individuals, found ICC values between 0.65 and 0.88, with single-subject second measurements showing random fluctuations of 1.9/0.5 times (SDNN) to 3.5/0.3 times (LF/HF) relative to the first, estimating required sample sizes of 24-98 subjects (PMID 17381425); Cipryan and Litschmannova similarly found large within-subject random variation in HRV parameters among 99 individuals (PMID 22963409); a 2025 study of 49 individuals over one week showed resting HRV ICC values of only 0.50-0.83 with coefficient of variation ranging from 5%-41%, with frequency-domain metrics being less stable than time-domain ones (PMID 39854840). This means: The HRV endpoint itself consumes power, requiring even larger sample sizes to detect the interaction term above the noise.

Conclusion: Power analysis must use simulation, not hand calculation. The Three-Quality × Four-Pathway design is a mixed design of 3 (between-subject) × 4 (within-subject), involving both cross-layer interactions and the variance structure of crossed designs; analytical formulas are inaccurate. The correct approach is Monte Carlo simulation: set gradients for main and interaction effect sizes (e.g., interaction = 1/3, 1/5 of main), the ratio of between-subject to within-subject variance, and sample sizes per cell (30-300 per Quality group), simulating power for interaction detection at each level to plot a “Sample Size-Power Surface” (methodological references: SIMR tutorial PMID 30265048, mixed-model simulation power PMID 33954914, Monte Carlo mapping power method PMID 22350626). If simulation shows that 300 subjects per Quality group still fails to reach 80% power, the design with “interaction as endpoint” should be abandoned or replaced by adaptive sample size re-estimation (PMID 30073679 provides methods for blinded and unblinded re-estimation in crossed trials).

In one sentence: 12 cells do not equal 12 times simplicity. Before discussing whether “Pathways differ by Quality,” first calculate whether this trial has the qualification to claim “non-significant.”

Evidence and Limitations

Verified: Interaction variance is four times main effect, requiring fourfold sample size (PMID 20084090); 80% power for overall effect yields only 29% for equivalent interaction, requiring >100x inflation if interaction <20% (PMID 15066682, PMID 11701102); efficiency gain for main effects in crossed designs relates to two variance components (PMID 28810895, PMID 9855035); small effects in cross-layer interactions remain undetectable even with 200 clusters (PMID 30265048); insufficient interaction power leads to misinterpretation (PMID 28746525, PMID 16279257); HRV retest reliability ICC 0.50-0.88, CV up to 41% (PMID 17381425, PMID 22963409, PMID 39854840); Monte Carlo simulation for power (PMID 33954914, PMID 22350626); sample size re-estimation in crossed trials (PMID 30073679).

Partially Verified: The prior assumption that “interaction effect magnitude is 1/3-1/5 of main effect” stems from mechanistic analogy—different qualities should show moderate differences in response to different pathways—but the interaction effect size for Three-Quality × Pathway has never been empirically measured; it is a key unknown parameter for this study’s power surface.

To Be Verified: True effect magnitude of the Three-Quality × Four-Pathway interaction; minimum sample size required for 80% power in a 12-cell crossed design; specific magnitude of the power gap for cross-layer interaction relative to main effect testing; additional dilution ratio of HRV measurement noise on interaction power; feasibility of blinded sample size re-estimation in Three-Quality crossed trials.

Related Reading

Evidence Level: B (Fourfold rule for interaction power, cross-layer interaction power, HRV reliability, and simulation power methods all have direct PubMed support; “Sample Size-Power Surface for 12-cell Three-Quality × Four-Pathway Design” lacks direct research and relies on methodological extrapolation plus simulated design reasoning)
References: PMID 20084090, PMID 15066682, PMID 11701102, PMID 16279257, PMID 28810895, PMID 9855035, PMID 30265048, PMID 28746525, PMID 17381425, PMID 22963409, PMID 39854840, PMID 33954914, PMID 22350626, PMID 30073679, PMID 40547334


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *